摘要
目的探究溃疡性结肠炎患者开展柳氮磺吡啶+复方甘草酸苷治疗的临床效果和安全性。方法择取2016年4月至2019年4月我院消化科收治的100例溃疡性结肠炎患者为研究对象,通过抽签法对患者进行完全随机分组,其中包括对照组和观察组,每组50例。两组均行柳氮磺吡啶治疗,观察组基于此使用复方甘草酸苷治疗,对两组患者血清白细胞介素6(IL-6)、白细胞介素8(IL-8)及肿瘤坏死因子α(TNF-α)等炎性因子水平,及药物治疗后的不良反应情况进行比较。结果观察组患者三项炎性因子水平均显著低于对照组,统计学软件显示组间差异有意义(P<0.05);观察组患者不良反应发生率为6.00%,对照组患者不良反应发生率为20.00%,统计学软件显示组间差异有意义(P<0.05)。结论溃疡性结肠炎患者的临床治疗中实施柳氮磺吡啶+复方甘草酸苷治疗具有良好的炎性症状改善效果,可降低不良反应风险,因此该种治疗方法值得在临床中大力推广。
Objective To explore the clinical efficacy and safety of sulfasalazine plus compound glycyrrhizin in the treatment of ulcerative colitis.Methods 100 patients with ulcerative colitis admitted to the Department of digestion of our hospital from April 2016 to April 2019 were selected as the research objects.The patients were randomly divided into control group and observation group,50 cases in each group.Both groups were treated with sulfasalazine.The observation group was treated with compound glycyrrhizin.The levels of serum inflammatory factors such as interleukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor-alpha(TNF-alpha)and the adverse reactions after treatment were compared between the two groups.Results The levels of three inflammatory factors in the observation group were significantly lower than those in the control group,and the statistical software showed significant difference between the two groups(P<0.05);the incidence of adverse reactions in the observation group was 6.00%,and that in the control group was 20.00%.The statistical software showed significant difference between the two groups(P<0.05).Conclusion Sulfasalazine plus compound glycyrrhizin can improve inflammatory symptoms and reduce the risk of adverse reactions in the clinical treatment of ulcerative colitis,so it is worth promoting in clinical practice.
作者
麻瑞娟
苟金平
MA Rui-juan;GOU Jin-ping(Department of Gastroenterology,Tianshui First People’s Hospital,Tianshui,Gansu 741000)
出处
《智慧健康》
2019年第29期100-101,120,共3页
Smart Healthcare
关键词
柳氮磺吡啶
复方甘草酸苷
溃疡性结肠炎
不良反应
炎性因子
Sulfasalazine
Compound glycyrrhizin
Ulcerative colitis
Adverse reactions
Inflammatory factors
